Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival

PURPOSE: Bevacizumab, a humanized monoclonal antibody to VEGF, is used routinely in the treatment of patients with recurrent glioblastoma (GBM). However, very little is known regarding the effects of bevacizumab on the cells in the perivascular space in tumors. EXPERIMENTAL DESIGN: Established ortho...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Müller-Greven, Gaëlle, Carlin, Cathleen R., Burgett, Monica E., Ahluwalia, Manmeet S., Lauko, Adam, Nowacki, Amy S., Herting, Cameron J., Qadan, Maha A., Bredel, Markus, Toms, Steven A., Lathia, Justin D., Hambardzumyan, Dolores, Sarkaria, Jann N., Hamerlik, Petra, Gladson, Candece L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690835/
https://ncbi.nlm.nih.gov/pubmed/28912141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0249
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia